Targeted Oncology

Afuresertib-Based Combination Meets Primary End Point in Phase 3 HR+ Breast Cancer Trial

Afuresertib plus fulvestrant cuts progression risk in HR+/HER2– metastatic breast cancer with PI3K/AKT/PTEN alterations, with ...